These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27595758)

  • 21. Testicular invading refractory multiple myeloma during bortezomib treatment successfully treated with lenalidomide: a case report.
    Miyao K; Sakemura R; Sakai T; Tsushita N; Kato T; Niimi K; Ono Y; Sawa M
    Ann Hematol; 2014 Mar; 93(3):529-30. PubMed ID: 23820941
    [No Abstract]   [Full Text] [Related]  

  • 22. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment.
    Chanan-Khan AA; San Miguel JF; Jagannath S; Ludwig H; Dimopoulos MA
    Clin Cancer Res; 2012 Apr; 18(8):2145-63. PubMed ID: 22328563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An overview of the progress in the treatment of multiple myeloma.
    Kyle RA; Rajkumar SV
    Expert Rev Hematol; 2014 Feb; 7(1):5-7. PubMed ID: 24433105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thalidomide and lenalidomide in multiple myeloma.
    Mazumder A; Jagannath S
    Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lenalidomide in patients with chemotherapy-induced polyneuropathy and relapsed or refractory multiple myeloma: results from a single-centre prospective study.
    Briani C; Torre CD; Campagnolo M; Lucchetta M; Berno T; Candiotto L; Padua L; Ermani M; Cavaletti G; Zambello R
    J Peripher Nerv Syst; 2013 Mar; 18(1):19-24. PubMed ID: 23521639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lenalidomide-induced regenerative macronodules infarction in a cirrhosis patient.
    Dangouloff-Ros V; Cervera P; Carbonell N; Arrivé L
    Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):213-5. PubMed ID: 23498774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myeloma kidney: the importance of assessing the response by monitoring free light chains in serum.
    Martín-Gómez MA; García-Marcos SA; Caba-Molina M; Palacios-Gómez ME; Gómez-Morales M; Claver-Ferré C
    Nefrologia; 2013 Nov; 33(6):862-4. PubMed ID: 24241381
    [No Abstract]   [Full Text] [Related]  

  • 28. [Thalidomide for the treatment of refractory multiple myeloma].
    Kakimoto T; Hattori Y; Okamoto S
    Rinsho Ketsueki; 2002 May; 43(5):345-8. PubMed ID: 12096483
    [No Abstract]   [Full Text] [Related]  

  • 29. Advances in oral therapy in the treatment of multiple myeloma.
    Doss DS
    Clin J Oncol Nurs; 2006 Aug; 10(4):514-20. PubMed ID: 16927905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Therapeutic outcomes in systemic lymphatic diseases and plasmacytoma. New hope for palliative patients].
    Heinrich B
    MMW Fortschr Med; 2005 Jun; 147(24):23. PubMed ID: 16001528
    [No Abstract]   [Full Text] [Related]  

  • 31. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
    Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
    Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
    Nijhof IS; Groen RW; Noort WA; van Kessel B; de Jong-Korlaar R; Bakker J; van Bueren JJ; Parren PW; Lokhorst HM; van de Donk NW; Martens AC; Mutis T
    Clin Cancer Res; 2015 Jun; 21(12):2802-10. PubMed ID: 25398450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolving role of novel agents for maintenance therapy in myeloma.
    Magarotto V; Palumbo A
    Cancer J; 2009; 15(6):494-501. PubMed ID: 20010169
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure.
    Dao K; Lu Y; Peer CJ; Figg WD; Stadelmann R; Burnier M; Buclin T; Kissling S
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):215-218. PubMed ID: 27988790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers.
    Oehrlein K; Langer C; Sturm I; Pönisch W; Hahn-Ast C; Kuhn S; Weisel KC
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):191-6. PubMed ID: 22341857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Desensitization to lenalidomide in a patient with relapsed multiple myeloma.
    Seki JT; Banglawala S; Lentz EM; Reece DE
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):162-5. PubMed ID: 23103087
    [No Abstract]   [Full Text] [Related]  

  • 38. Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients.
    Guglielmelli T; Bringhen S; Rrodhe S; Gay F; Cavallo F; Berruti A; Montefusco V; Piro E; Benevolo G; Petrucci MT; Caravita T; Offidani M; Corradini P; Boccadoro M; Saglio G; Palumbo A
    Eur J Cancer; 2011 Apr; 47(6):814-8. PubMed ID: 21334196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A longitudinal computed tomography study of lenalidomide and bortezomib treatment for multiple myeloma: trabecular microarchitecture and biomechanics assessed using multidetector computed tomography.
    Takasu M; Tani C; Kaichi Y; Sakoda Y; Kiguchi M; Date S; Kuroda Y; Sakai A; Awai K
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):485-92. PubMed ID: 25190250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. From the guest editor: the evolving treatment paradigm in multiple myeloma.
    Anderson KC
    Cancer J; 2009; 15(6):456. PubMed ID: 20010163
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.